Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Zealand Pharma (ZEAL)

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Zealand Pharma (ZEAL)

192 Posts
Pagina: «« 1 2 3 4 5 6 ... 10 »» | Laatste | Omlaag ↓
  2. [verwijderd] 29 oktober 2018 11:33
    Ik heb mij sinds vorige week ingelezen in Zealand en moet zeggen dat ik het er erg hoopgevend uit vind zien. De fase 3 studies zien er goed uit en is een gezonde kaspositie. De koers (en de markt) zijn laten over het geheel alleen een ander verloop zien. Dus waarom zou je nu bij willen kopen Wil? Waarom niet de neerwaartse trend afwachten en bij een stijging kopen?
    Bijlage:
  4. Wil Helmus 30 oktober 2018 09:23
    Ik zie Zealand als een investering voor de langere termijn. Op dit moment nog geen producten op de markt, maar het ziet er allemaal erg goed uit. Drie fase 3 producten waarvan 2 een orphan status hebben (Dasiglucagon voor de behandeling van CHI zelfs bij de FDA en EMA). Door deze status hebben ze na goedkeuring 7 jaar markt exclusiviteit. En er is genoeg geld in kas. Een emissie is dus voorlopig niet nodig. Als je long zit maakt het volgens mij niet uit of je ze voor 80 of 85 DKK koopt
  7. forum rang 10 DeZwarteRidder 9 maart 2019 17:22
    A potential treatment for the opposite of diabetes

    Chuck Saletta (Zealand Pharma): Diabetes is an awful disease that affects over 400 million people around the world. It is frequently lifelong, with life-threatening consequences if left untreated or unmanaged. Yet despite the consequences of diabetes, there are some people for whom it beats the alternative diagnosis: a disease called congenital hyperinsulinism.

    While it's a fairly rare disease, affecting around 1 in 50,000 newborns, congenital hyperinsulinism can cause permanent brain damage. As a result, many with the disease have part or all of their pancreas removed, which can ultimately lead to diabetes.

    Zealand Pharma has a potential treatment for congenital hyperinsulinism, dasiglucagon, that just entered phase 3 clinical trials. If it is successful, it could prevent the need for patients to have their pancreas removed -- allowing them to live far more normal lives without developing diabetes as a "less awful" alternative. The same compound is in trials to treat other forms of hypoglycemia -- including hypoglycemia that results from mis-dosed insulin in diabetics.

    That ability to treat multiple forms of hypoglycemia makes dasiglucagon a compound with a billion-dollar-a-year market potential if it passes its phase 3 trials. Zealand Pharma's current market capitalization is around half that amount, which makes it an intriguing candidate for consideration as a potential investment.

    If the phase 3 tests for dasiglucagon prove successful, Zealand Pharma expects to file a new drug application by the end of this year. That gives investors a limited window to buy before a decision is made that could result in a major move in the company's stock. Note that Zealand Pharma is not currently profitable, driven by its heavy research and development budget, which means that it is a high-risk investment despite the potential reward if it's successful.
  8. Wil Helmus 12 maart 2019 12:30
    That ability to treat multiple forms of hypoglycemia makes dasiglucagon a compound with a billion-dollar-a-year market potential if it passes its phase 3 trials.

    ...........with readout in H1 2019 and with an expected New Drug Application (NDA) filing H2 2019.

    Nog een paar maandjes geduld, dan gaat dit aandeel knallen
  10. Wil Helmus 13 maart 2019 08:14
    Zealand Pharma announces full-year 2018 results, strong cash position to support pipeline progress

    Business highlights and updates for Q4 2018 and the period thereafter:

    •Glepaglutide for short bowel syndrome: Phase 3 initiated and on track for 2020 results; 12 patients randomized as of March 6, 2019.
    •Dasiglucagon HypoPal® rescue pen for severe hypoglycemia: Remaining clinical trials initiated; on track for mid-2019 results and subsequent NDA filling with the FDA.
    •Dasiglucagon for the treatment of congenital hyperinsulinism: First patient randomized in Phase 3 trial as of March 6, 2019.
    •Dasiglucagon for the treatment of diabetes in dual-hormone pumps: DKK 22.8million (USD 3.5 million) equity investment in strategic partner Beta Bionics.
    •ZP7570, a long-acting GLP-1/GLP-2 agonist selected as a new clinical candidate, accompanied by decision to cease further development of elsiglutide.
  12. Wil Helmus 20 maart 2019 13:52
    Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases

    Company announcement – No. 06 / 2019



    Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
    •Collaboration furthers Alexion’s complement leadership with expansion into peptide therapies.
    •Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway.
    •Zealand Pharma to receive upfront payment of $25 million and equity investment of $15 million, with potential for additional milestone-dependent and royalty payments.
    •Collaboration further strengthens Zealand Pharma’s position as a leading developer of next generation peptide-based therapeutics.

    BOSTON & COPENHAGEN, Denmark, March 20, 2019 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Zealand Pharma A/S (NASDAQ: ZEAL) today announced a collaboration to discover and develop novel peptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being highly selective and potent, allowing low dosage volumes for ease of administration, and having the potential to treat a broad range of complement-mediated diseases. The agreement provides Alexion with exclusive worldwide licenses, as well as development and commercial rights, for up to four targets within the complement pathway.

    “We know that uncontrolled activation of the complement pathway is responsible for many devastating diseases, and through the development of the first two complement inhibitors – SOLIRIS and ULTOMIRIS – we have shown the transformative impact of C5 inhibition on several of these diseases,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion. “We are excited by the potential to explore different targets in the complement pathway and look forward to building on Alexion’s more than 20 years of complement expertise with the development of next-generation peptide therapies in collaboration with Zealand Pharma, which may provide the opportunity to treat many additional diseases.”

    “Collaborating with Alexion is further evidence of the strength of our peptide discovery platform, which has delivered both approved novel peptide-based therapeutics and a deep late-stage pipeline,” said Adam Steensberg, Interim CEO and Chief Medical and Development Officer at Zealand. “We believe that peptide-based therapies hold great promise in inhibiting complement activation. Alexion’s demonstrated expertise in treating rare and complement-mediated diseases makes this the ideal collaboration to advance Zealand’s complement-focused peptide programs.”

    Under the terms of the agreement, Alexion and Zealand will enter into an exclusive collaboration for the discovery and development of subcutaneously delivered peptide therapies directed to up to four complement pathway targets. Zealand will lead the joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with IND filing and Phase 1 studies. The agreement provides Alexion with exclusive worldwide licenses and commercial rights to the peptide therapies developed in the collaboration. Zealand will receive an immediate upfront payment of $25 million for the first target, with Alexion making a concurrent $15 million equity investment in Zealand Pharma at a premium to the market price as of the collaboration effective date. For the lead target, the agreement provides the potential for development-related milestones of up to $115 million, as well as up to $495 million in sales-related milestones and the potential for high single- to low double-digit royalty payments. Each of the three subsequent targets can be selected for an option fee of $15 million and has the potential for additional development-milestones and sales-milestones and royalty payments at a reduced price to the lead target.

    Alexion will discuss the collaboration further during today’s Investor Day event and webcast. Zealand will host a conference call on Thursday, March 21, at 4 p.m. CET.
  13. GorillaGlue 21 maart 2019 16:47
    Company announcement – No. 8/2019

    Zealand Pharma announces completion of the share subscription by Alexion Pharmaceuticals, Inc. and registration of capital increase



    Zealand Pharma A/S has today registered a capital increase of 802,859 new shares and completed the share subscription by Alexion Pharmaceuticals, Inc.

    Copenhagen, March 21, 2019 – With reference to the company announcements no. 6/2019 dated March 20, 2019 and 7/2019 dated March 20, 2019 regarding the entering into of the license agreement with Alexion Pharmaceuticals, Inc. and the associated share subscription, Zealand announces that it has today increased its share capital by nominally DKK 802,859, divided into 802,859 new shares with a nominal value of DKK 1 each (the “New Shares”), at a subscription price of USD 18.68 per New Share (corresponding to approximately DKK 123), corresponding to an aggregate subscription price for the New Shares USD 15 million (corresponding to approximately DKK 98.5 million).

    Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 31,661,686 divided into 31,661,686 shares with a nominal value of DKK 1 each.

    The New Shares rank pari passu with Zealand’s existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

    The New Shares have been issued today and are expected to be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible in the permanent ISIN code DK0060257814.

    The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.

    For further information, please contact:

    Adam Steensberg, Interim Chief Executive Officer,
    Executive Vice President and Chief Medical & Development Officer
    Tel: +45 50 60 36 01, e-mail: ast@zealandpharma.com

    Mats Blom, Executive Vice President, Chief Financial Officer
    Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

    About Zealand Pharma A/S
    Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

    Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

    Copenhagen, March 21, 2019 – With reference to the company announcements no. 6/2019 dated March 20, 2019 and 7/2019 dated March 20, 2019 regarding the entering into of the license agreement with Alexion Pharmaceuticals, Inc. and the associated share subscription, Zealand announces that it has today increased its share capital by nominally DKK 802,859, divided into 802,859 new shares with a nominal value of DKK 1 each (the “New Shares”), at a subscription price of USD 18.68 per New Share (corresponding to approximately DKK 123), corresponding to an aggregate subscription price for the New Shares USD 15 million (corresponding to approximately DKK 98.5 million)

    Hoe moet ik dit lezen? Is dit nou een emissie op hogere prijs dan de beurskoers (en waarom noteert het aandeel op DKK 117.80 ipv 123)?
  15. Wil Helmus 6 mei 2019 20:48
    Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019

    Press Release – No. 09 / 2019

     

    Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019

    Copenhagen, May 6, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR no. 20 04 50 78) announces that it will host a conference call on May 16, 2019 at 4 pm CET/10 am EST following the announcement of results for the first three months of 2019.

  16. Wil Helmus 7 mei 2019 14:21
    Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

    Press release – No. 10 / 2019

    Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
    •The Phase 3 extension trial will evaluate long-term safety and efficacy of glepaglutide and enrolls short bowel syndrome (SBS) patients that have completed the pivotal Phase 3 trial.

    •The pivotal Phase 3 registration trial with glepaglutide for the treatment of SBS remains on track with results expected in 2020.

    •Glepaglutide is a long-acting GLP-2 analog with potential for once-weekly dosing in an auto-injector pen.

    Copenhagen, May 7, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has enrolled the first patient in a Phase 3 extension trial to evaluate the long-term safety and efficacy of glepaglutide treatment in patients with short bowel syndrome (SBS).

    Patients who have completed either of the preceding Phase 2 and Phase 3 trials for glepaglutide as treatment for SBS may be eligible to participate in the Phase 3 extension trial. Safety and efficacy will be evaluated throughout a two-year duration.

    “We are focused on improving the lives of people living with short bowel syndrome, and this extended trial demonstrates our commitment to delivering better treatment options for SBS,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “We are grateful for the SBS patients that participate in our clinical studies. It’s our intention that this extension trial will help patients continue their pursuit of better health outcomes by improving intestinal absorption with glepaglutide.”

    “Transitioning SBS patients into the glepaglutide extension trial is a positive advancement. We interpret it as a sign of good study conduct as well as good tolerability of the product,” added Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma.

    Additional details about the Phase 3 extension trial of glepaglutide to treat SBS can be found on ClinicalTrials.gov.

    For further information, please contact:

    Emmanuel Dulac, President and Chief Executive Officer
    Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

    Lani Pollworth Morvan, Investor Relations and Communication
    Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

    About short bowel syndrome (SBS)
    SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

    About glepaglutide
    Glepagtluide is a long-acting GLP-2 analog being developed in an auto-injector with potential for convenient weekly administration as treatment for short bowel syndrome (SBS). Zealand Pharma aspires to provide the next generation, best-in-class therapies to help transform the lives of people living with SBS. Glepaglutide has the potential to be a best-in-class GLP-2 therapy, allowing people with SBS a fast, reliable and well-tolerated treatment option to reduce dependence on parenteral support.

    About Zealand Pharma A/S
    Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

    Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
  17. rbot 14 mei 2019 10:49


    Company announcement – No. 15 / 2019

    Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia

    Primary and all key secondary endpoints successfully achieved in the trial
    Median time to recovery from low blood glucose was 10 minutes following dasiglucagon injection administered via the HypoPal® rescue pen
    The dasiglucagon HypoPal® rescue pen is being developed as an easy-to-use, fast and effective rescue treatment for diabetes patients having a severe hypoglycemic event

    Copenhagen, May 14, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces successful results in the confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes. Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal® rescue pen, an auto-injector for easy, fast and effective treatment of severe hypoglycemia in people with diabetes.

    This Phase 3 trial confirms that a single dose of dasiglucagon administered via the HypoPal® rescue pen rapidly increases blood glucose levels in patients with type 1 diabetes following insulin-induced hypoglycemia. The trial compared the glycemic response observed after dosing of dasiglucagon with that of placebo. The primary endpoint was time to plasma glucose recovery, which was defined as first increase in plasma glucose of =20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. 45 subjects were included in the trial. Additional details about the trial are found at clinicaltrials.gov.

    The primary result demonstrates that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was superior to placebo (median: 35 min; p<0.001) and identical to a median time to rescue of 10 minutes observed in the pivotal Phase 3 trial which used a pre-filled syringe for administration of dasiglucagon. Likewise, the dasiglucagon pharmacokinetic profiles were consistent between the two trials. Overall, no safety concerns were raised for dasiglucagon within the trial. Nausea and vomiting were reported with dasiglucagon (nausea: 62% and vomiting: 29%) and were on par with the frequency observed in the pivotal Phase 3 trial (nausea: 55% and vomiting: 23%).

    Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma, commented: “I am very encouraged by the outcome of this Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in diabetes. The study used the to-be-marketed HypoPal® rescue pen, and the results underscore the fast and effective profile of dasiglucagon also seen in the pivotal Phase 3 trial utilizing a pre-filled syringe.”

    This is the third consecutive Phase 3 trial with positive results for dasiglucagon. The previous immunogenicity and pivotal Phase 3 trials established dasiglucagon’s safety profile and fast onset of action when administered via a pre-filled syringe in adult patients with type 1 diabetes. The final Phase 3 trial that will complete our NDA application is in pediatric diabetes patients and is still ongoing. Recruitment for this study involving children has proved challenging and results are now expected in September 2019. Accounting for this delay in pediatric patient recruitment, submission of the new drug application (NDA) to the U.S. FDA is now expected early 2020.

    “I am very impressed with the dasiglucagon HypoPal® rescue pen data and believe its innovative features have the potential to significantly transform management of severe hypoglycemia,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Helping a diabetic patient through an acute crisis of severe hypoglycemia can be a highly traumatic experience. Our vision is for every patient at risk of severe hypoglycemia to have the HypoPal® rescue pen readily available.”
  18. Wil Helmus 14 mei 2019 11:20
    quote:

    Wil Helmus schreef op 12 maart 2019 12:30:

    That ability to treat multiple forms of hypoglycemia makes dasiglucagon a compound with a billion-dollar-a-year market potential if it passes its phase 3 trials.

    ...........with readout in H1 2019 and with an expected New Drug Application (NDA) filing H2 2019.

    Nog een paar maandjes geduld, dan gaat dit aandeel knallen
    Geweldig nieuws!
  20. Wil Helmus 22 mei 2019 16:14
    Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

    Zealand Pharma Press Release – No. 11 / 2019

    Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes
    •First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled, commercial-ready, pump cartridge has been initiated by a clinical team at Massachusetts General Hospital

    •The iLet Bionic Pancreas System is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes

    •Dasiglucagon is a potential first-in-class stable glucagon analog

    Boston, MA and Copenhagen, Denmark, May 22, 2019 – Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL) announced today the first patients dosed in a clinical trial investigating the home-use of dasiglucagon in the iLet™ Bionic Pancreas System. The iLet, developed by Beta Bionics, is the world’s first autonomous bionic pancreas device — a bihormonal system leveraging lifelong machine learning and artificial intelligence to deliver insulin and glucagon analogs for the autonomous treatment of type 1 diabetes. In addition to dosing insulin, the iLet doses dasiglucagon — a glucagon analog developed by Zealand Pharma with a unique stability profile in a ready-to-use aqueous solution.

    This home-use clinical trial is being conducted by Dr. Steven Russell and his clinical research team at the Massachusetts General Hospital. The current trial is designed as a randomized, two-arm, cross-over trial to assess whether the iLet operates as designed. It compares the operational performance of the iLet in its insulin-only configuration to its bihormonal configuration using dasiglucagon in adults with type 1 diabetes. Secondary objectives of the study include assessing the impact of the insulin-only and bihormonal configurations of the iLet Bionic Pancreas System on glycemic control, quality of life, and treatment satisfaction among study participants, their caregivers, partners, and/or family members.

    “The start of this home-use clinical trial with the iLet in its bihormonal configuration — autonomously and independently pumping both insulin and Zealand’s dasiglucagon — marks the achievement of a long-awaited and eagerly anticipated milestone,” said Ed Damiano, Co-founder and President & CEO of Beta Bionics.

    Beta Bionics and Zealand Pharma have partnered to carry out several co-development activities with the primary goal of obtaining regulatory approval to use dasiglucagon in the bihormonal configuration of the iLet.

    “Fully automated diabetes care, realized by a dual-hormone artificial pancreas system using insulin together with dasiglucagon, could significantly improve life for millions of people living with type 1 diabetes,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma.



    For further information, please contact:

    Beta Bionics Zealand Pharma


    Ed Damiano
    edamiano@betabionics.com



    Ed Raskin
    eraskin@betabionics.com



    Investor Relations Contact
    Jeremy Feffer
    jeremy@lifesciadvisors.com



    Emmanuel Dulac
    President and Chief Executive Officer
    +45 50 60 36 36
    edu@zealandpharma.com



    Lani Pollworth Morvan
    Investor Relations and Communication
    +45 50 60 37 78
    lpm@zealandpharma.com



    About the iLet
    The iLet bionic pancreas system is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes. The lifelong, machine-learning, mathematical dosing algorithms integrated into the iLet were licensed by Beta Bionics from Boston University. In previous home-use studies in adults and children with T1D, these algorithms demonstrated dramatic improvements in glycemic control relative to the standard of care. These improvements included significant reductions in blood-glucose levels, in hypoglycemia, and in intersubject and intrasubject glycemic variability (New England Journal of Medicine. 2014, 371:313-25; Lancet Diabetes and Endocrinology. 2016, 4:233-43; Lancet. 2016, 389:369-80).

    To initialize the iLet, users enter only their body weight. Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections. The iLet is effectively three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas (insulin and glucagon). The glucagon-only configuration may be helpful in rare, chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI) and insulinoma syndrome. Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.

    About dasiglucagon for use in other indications
    Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of severe hypoglycemia, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

    About Beta Bionics
    Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas system that is driven by machine-learning artificial intelligence to autonomously control glycemia. These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation™ whose founders—in addition to Ed Damiano—include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.

    Beta Bionics is operated out of Boston, Massachusetts and Irvine, California. For further information, please visit www.betabionics.com or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.

    About Zealand Pharma A/S
    Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

    Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
192 Posts
Pagina: «« 1 2 3 4 5 6 ... 10 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0655 +0,11%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.714,20 -0,69%
Gold spot 2.392,50 0,00%
NY-Nasdaq Composite 15.282,01 -2,05%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!